| 01.04.24 | Deals galore: Novo Nordisk, Roche, Boehringer and more; Innate quickly dispatches with FDA hold

Fiercebiotech.com

Klicken Sie hier, um Fiercebiotech.com zu abonnieren

Laden...

10 Monate vor

Html
Text

Today’s Big News

Jan 4, 2024

Novo Nordisk offers 2 Flagship biotechs up to $1B total for obesity, MASH deals

Innate secures speedy resolution of FDA hold on lymphoma trials ahead of key regulatory talks

Fierce Biotech Fundraising Tracker '24: HI-Bio secures $95M; Radionetics raises $52.5M

AI is 'not a panacea' for all drug discovery challenges, but partnerships can be for Generate

Boehringer double dips at 3T, inking second T-cell anticancer deal to swell potential payday to $538.5M

Bayer's AskBio checks off another early win for gene therapy platform with Parkinson's safety data

Moma’s the word as Roche signs $2B biobucks deal to develop precision cancer drugs

Menarini Group’s Stemline inks $500M+ biobucks deal for Insilico’s breast cancer candidate

Avenzo, Merck KGaA and AbbVie each ink new deals to fortify cancer pipelines

ADC Therapeutics, Aldeyra start off New Year with program discontinuations

Galapagos wants to find new small molecule species for cancer with BridGene


A message from Digital Pharma East

Featured

Novo Nordisk offers 2 Flagship biotechs up to $1B total for obesity, MASH deals

By Gabrielle Masson

As part of a pact with Flagship Pioneering, Novo Nordisk has inked separate cardiometabolic disease research deals with two Flagship-founded biotechs that are worth up to $532 million each.

Innate secures speedy resolution of FDA hold on lymphoma trials ahead of key regulatory talks

By Nick Paul Taylor

Innate Pharma has begun the new year with a spring in its step, sharing news that the FDA has lifted the partial hold on lymphoma clinical trials that was imposed last year in response to the death of a patient.

Fierce Biotech Fundraising Tracker '24: HI-Bio secures $95M; Radionetics raises $52.5M

By Gabrielle Masson,Annalee Armstrong

Welcome to Fierce Biotech's Fundraising Tracker, 2024's version.

AI is 'not a panacea' for all drug discovery challenges, but partnerships can be for Generate

By Annalee Armstrong

Generate Biomedicines CEO Mike Nally is heading to the J.P. Morgan Healthcare Conference in San Francisco to build relationships for the AI biotech’s next partnerships.


A message from Citeline

Boehringer double dips at 3T, inking second T-cell anticancer deal to swell potential payday to $538.5M

By Nick Paul Taylor

Boehringer Ingelheim’s business development team has scorched out of the traps in 2024. Thursday, the German drugmaker unveiled its second deal of the year, revealing another T-cell anticancer therapy partnership with 3T Biosciences to swell the potential payday to $538.5 million.

Bayer's AskBio checks off another early win for gene therapy platform with Parkinson's safety data

By Annalee Armstrong

Bayer’s AskBio gene therapy unit has achieved a key safety milestone in an early-stage trial for an investigational Parkinson’s disease treatment that must be delivered surgically into the brain.

Moma’s the word as Roche signs $2B biobucks deal to develop precision cancer drugs

By James Waldron

Two days after joining the antibody-drug conjugate (ADC) race, Roche has signed another cancer-focused licensing deal.

Menarini Group’s Stemline inks $500M+ biobucks deal for Insilico’s breast cancer candidate

By Gabrielle Masson

Menarini Group’s Stemline Therapeutics is paying $12 million upfront for licensing rights to Insilico Medicine’s cancer candidate in a deal potentially worth more than $500 million.

Avenzo, Merck KGaA and AbbVie each ink new deals to fortify cancer pipelines

By Max Bayer

With JPM on the horizon, the dealmaking landscape is ablaze with opportunity. Avenzo, Merck KGaA and AbbVie are just the latest to sign onto new pacts.

ADC Therapeutics, Aldeyra start off New Year with program discontinuations

By Gabrielle Masson

For ADC Therapeutics and Aldeyra, ringing in the new year means leaving certain programs behind in 2023.

Galapagos wants to find new small molecule species for cancer with BridGene

By Annalee Armstrong

BridGene Biosciences has arrived on Galapagos island thanks to a $27 million upfront deal to develop new small molecule drugs for cancer.

Pfizer rings in New Year with hemophilia B gene therapy nod in Canada

By Eric Sagonowsky

After a pair of high-profile approvals for sickle cell disease gene therapies in the U.S. last month, Pfizer is ushering in the New Year with a regulatory endorsement for its hemophilia B gene therapy north of the border.

Velocity accelerates European growth with acquisitions in Poland and Germany

By Joseph Keenan

Velocity Clinical Research has expanded its footprint in Europe with the acquisitions of three clinical site networks in Poland and Germany.

Hospital, payer price transparency compliance improves, but new requirements are kicking in this year

By Dave Muoio

A state-of-the-industry report released Thursday found steady improvements in the number of organizations releasing price data, as well as the comprehensiveness and usability of those data. However, new enforcement in effect with the New Year could see noncompliant hospitals' warnings letters issued to the public.

Bain Capital eyes potential €1B sale of Dutch antibiotics manufacturer Centrient: report

By Fraiser Kansteiner

Investment giant Bain Capital is weighing a potential sale of its Dutch antibiotics and active pharmaceutical ingredients (API) specialist Centrient Pharmaceuticals, which could be valued as high as €1 billion ($1.09 billion), Bloomberg reported Wednesday, citing people close to the talks.

Fierce podcasts

Don’t miss an episode

'The Top Line': The year in biotech

This week on "The Top Line," Fierce Biotech staff writer Gabrielle Masson and senior editor Annalee Armstrong look back at the year in biotech, which was defined by massive layoffs across the industry. They also discuss their favorite stories of the year, including an appearance from a popstar whose reputation precedes her.

'Podnosis': Navigating the AI hype in healthcare

'The Top Line': A closer look at the Fierce 50

Webinar: Diverse Voices, Better Care: The Role of PROs in Advancing Health Equity

Wednesday, January 24, 2024 | 2pm ET / 11am PT

Join our webinar to hear from experts on how digital collection of patient-reported outcomes (PROs) can lay the foundation for advancing health equity, which methods can ensure that PROs are relevant for diverse populations, and what challenges and opportunities still lie ahead. Register now.

Resources

Whitepaper

Developing and Manufacturing Drugs with HPAPIs

Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient.

Catalent

eBook

7 “Make or Break” Factors for Emerging Biopharma Companies

This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.

Presented by Blue Matter, strategic consultants in the life sciences

Whitepaper

Quantify microbial biomarkers with high sensitivity and dynamic range

qPCR Assay Design - Quantify microbial biomarkers with high sensitivity and dynamic range

Pathway to GMP Expectations for Gene-Modified Cell Therapies

Streamline your clinical cell therapy with our GMP-compliant ribonucleoprotein (RNP) manufacturing as you scale up without compromising on quality to tackle complex regulatory requirements.

Fed-Batch Intensification To Increase Titer In Biologics Manufacturing

Improving efficiency and productivity in biologics manufacturing is a longstanding goal within today’s industry, especially now as new and increasingly complex molecules are fundamentally changing technological and operational approaches to drug development. Process intensification can help accelerate this pace of innovation through advanced process development techniques and high productivity manufacturing platforms.

Effective Technology Transfers for Mammalian-Derived Biologics

As a leader of technology transfer activities in the industry, Lonza understands the challenges associated with this critical step. Download this White Paper today to learn more.